Midazolam With Meperidine and Dexmedetomidine vs. Midazolam With Meperidine and Propofol for Sedation During ERCP

• Status: Completed
• Trial end date: 2017-01-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center, prospective, randomized, double-blinded study of consecutive patients referred for ERCP. A recent study suggested that the addition of dexmedetomidine to the midazolam-meperidine regimen (MMD)provided better sedative efficacy and a superior safety profile during ERCP compared with a midazolam-meperidine regimen. Further study is warranted to compare an MMD regimen with propofol-based regimen.

Randomization is performed by use of a computer-generated random allocations in a ratio of 1:1 in balanced blocks of 4. A separate sedating nurse, who don't participate in the study, is the only person with knowledge of the sedation regimen. This separate nurse repeated the injection of propofol and completed questionnaires.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dankook University
• Treatments: Dexmedetomidine; Meperidine; Midazolam; Propofol

Criteria

Inclusion Criteria:

• Those who are scheduled for ERCPs

• aged 18 to 80 years

• American Society of Anesthesiologists (ASA) classification I to III

Exclusion Criteria:

• ASA IV and V

• History of allergies to drug used

• refuse to participate the study